|Podcasts|January 23, 2018

Episode 1: 2018 Trends

In this podcast, Pharmaceutical Executive editors, Christen Harm and Michelle Maskaly, discuss the 2018 pharma trends, specifically biosimilars and eEnablement, and takeaways from the 2017 Veeva European Commercial Summit.

In this episode, Pharmaceutical Executive editors discuss the 2018 pharma trends, specifically biosimilars and eEnablement, and takeaways from the 2017 Veeva European Commercial Summit.

The podcast can be downloaded directly from SoundCloud, iTunes, GooglePlay, Stitcher, and Overcast.

 

 


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.